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Background: Familial Hyperparathyroidism (HPT) and Familial benign Hypocalciuric Hypercalcemia (FHH) are the
most common causes of hereditary hypercalcemia. FHH has been demonstrated to be caused by inactivating
mutations of calcium-sensing receptor (CaSR) gene, involved in PTH regulation as well as in renal calcium excretion.
Case presentation: In two individuals, father and son, we found a novel heterozygous mutation in CaSR gene. The
hypercalcemia was present only in father, which, by contrast to the classic form of FHH showed hypercalciuria
(from 300 to 600 mg/24 h in different evaluations) and a Calcium/Creatinine ratio of 0.031, instead of low or normal
calciuria (<0.01 typical finding in FHH). His son showed the same mutation in CaSR gene, but no clinical signs or
hypercalcemia although serum ionized calcium levels were close to the upper limit of normal values (1.30 mmol/L:
normal range: 1.12-1.31 mmol/L). Sequence analysis revealed a point mutation at codon 972 of CaSR gene
(chromosome 3q), located within cytoplasmic domain of the CaSR, that changes Threonine with Methionine. The
father was treated with Cinacalcet 90 mg/day, with a decrease of total serum calcemia from an average value of
12.2 mg/dl to 10.9 mg/dl.
Conclusion: This is a case of a novel inactivating point mutation of CaSR gene that determines an atypical clinical
presentation of FHH, characterized by hypercalcemia, hypercalciuria and inadequate normal PTH levels. Functional
assay demonstrated that the 972 M variant influenced the maturation of the protein, in terms of the post-translational
glycosylation. The impairment of the receptor activity is in keeping with the specific localization of the 972 residue in
the C-terminal tail, assigned to the intracellular signalling, that on the basis of the our findings appears to be differently
modulated in parathyroid gland and in kidney.
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CaSR gene (chr. 3q13.3-21) encodes for a protein of
1078 aminoacids present in the plasma membrane as a
dimer. CaSR is a member of the G-protein coupled re-
ceptors and its structure has 3 different domains [1,2].
The extracellular domain (612 aminoacids) binds extra-
cellular calcium through its multiple negative charges
allowing the CaSR to function as a sensitive detector
of extracellular calcium; the transmembrane part (250* Correspondence: mauro.cignarelli@unifg.it
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article, unless otherwise stated.aminoacids) has 7 membrane-spanning domains; the
intracellular tail (216 aminoacids) interacts with the G-
proteins and filamin A to translate within the cells the
signal produced by the extracellular calcium binding
[3,4]. Through these and other pathways, CaSR may in-
fluence cell function, especially PTH secretion from
parathyroid cells, but also cell proliferation and gene ex-
pression [5,6]. This process takes place mainly in para-
thyroid and kidney tubular cells, regulating calcium
concentrations in extracellular fluid. In the kidney, the
CaSR performs different tasks depending on the various
tubular segments in which it is located [7]. It is
expressed on the luminal membrane of the proximalentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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concentrations and inhibits cAMP production induced by
PTH [8,9]. CaSR is expressed on the basolateral membrane
of the thick ascending limb of Henle loop [9], where modu-
lates the electric gradient generated by sodium-potassium
reabsorption and potassium recycling, inhibiting the
sodium-potassium-chloride carrier activity. Therefore,
after an increase in serum calcium, CaSR decreases the
potential, eventually supporting calcium reabsorption
and promoting calcium excretion [5]. In the distal con-
voluted tubule, CaSR is located on the basolateral mem-
brane of tubular cells where reduces the active calcium
reabsorption by interfering with the calcium pump
function through a phospholipase C dependent mech-
anism [10]. In adults, inactivating mutations of CaSR
gene are found in FHH, an autosomal dominant disease
characterized by moderate but significant hypercalce-
mia, accompanied by few symptoms [11,12], with in-
appropriately normal serum PTH levels, and by a low or
normal urinary calcium levels [12-14] with histologi-
cally normal parathyroid glands. The condition does not
require treatment, and responds poorly to parathyroid-
ectomy. FHH should be distinguished from primary
HPT, in which the elevated serum and urinary calcium
levels are normalized by successful parathyroid surgery.
Familial primary HPT is inherited as autosomal domin-
ant mutation either as the single lesion (isolated HPT
form) [15] or in the context of multiple endocrine neo-
plasia (MEN) type 1 or 2A [16] and the HPT-jaw tumor
syndrome [17].
Case presentation
A 68-year-old male patient presented with slight fatigue
and intermittent polyuria. His family history was positive
for osteoporosis, negative for fractures and nefrolitiasis.
In childhood he was subjected to a jaw cementoma
asportation. He underwent several surgical procedures
because of recurrent nefrolitiasis since 25 years. He has
also been on hypertension treatment since 30 years. AtTable 1 Laboratory results (follow up period)
First values 1 year fo
(after cin
s-Ca total (correct) (n.v. 8.8-10.6) 11.6 mg/dl 10.9 m
s-PO4 (n.v. 2.7-4.5) 3 mg/dl 2.5 m
s-Creatinine (n.v. 0.2-1.2) 1.08 mg/dl 1.12 m
s-PTH (n.v. 5–40) 25.7 pg/ml 33 m
25(OH)vitamin D (n.v. 30–100) 16 ng/ml 16 ng
U Ca (n.v. < 4 mg/Kg) - 658 mg
Cr Clearance (n.v. 70–120 ml/min) - 67 ml/
Ca/Cr ratio - 0.04presentation we observed arterial pressure of 120/70 mmHg
and pulse rate of 70 beats/min with his habitual antihyper-
tensive therapy (Losartan 50 mg/day). Physical examin-
ation was unremarkable: weight 75 Kg, height 173 cm,
body mass index 25.1 Kg/m2. Total serum calcium level at
first evaluation was 11.6 mg/dl, with a PTH improperly
normal (25.7 pg/ml). Low values of serum 25-hydroxy-
Vitamin D3 was also observed (16 ng/ml). During the
following visits we found hypercalciuria (from 300 to
600 mg/24 h in different evaluations) and a Ca/Cr ratio
of 0.031. Glycemia, TSH, prolactin, IGF-1, urine meta-
nephrines levels were in normal range. We found higher
values of serum Anti-Parietal-Cells-Antibodies (APCA),
suggestive for chronic autoimmune gastritis. Laboratory
results are shown in Table 1.
Neck echography, NMR and 99mTc-sesta MIBI tomos-
cintigraphy were negative for parathyroids glands images.
Abdomen echography and CT showed bilateral polycystic
kidney (maximum diameter 8.5 cm). Bone density scan
(DXA) showed normal bone mineral density (Femur T-
score 1.07, Lumbar T score 1.3). Recent orthopantomogra-
phy was negative for jaw lesions.
The patient was treated for 7 months with Cinacalcet
90 mg/day, since at that time we ignored the existence of
the CaSR mutation. However, although Cinacalcet is not in-
dicated for FHH treatment, we obtained a slight decrease
of calcemia, but the therapy was stopped because of side ef-
fects appearance (hypotension, nausea). Subsequently, he
refused other specific therapies. During a 4 years follow-up
period hypercalcemia, hypercalciuria and normal levels of
PTH persisted. A heterozygous mutation in exon 7 of the
CaSR gene was found, predicting a p.T972M amino acid
substitution in cytoplasmic tail of CaSR (Figure 1). The
same mutation we found in one of his three screened sons,
a 41-year-old men (Figure 2), who is currently asymptom-
atic and shows serum ionized calcium level of 1.30 mmol/
L, close to the upper normal limit (n.v. 1.12-1.31), normal
calciuria (195 mg/24 h) and PTH, but also a 25 hydroxy-







g/dl 12.96 mg/dl 11.8 mg/dl
g/dl 2.2 mg/dl 2.4 mg/dl
g/dl 1.31 mg/dl 1.19 mg/dl
g/dl 19.4 mg/dl 25.4 mg/dl
/ml 40.7 ng/ml -
/24 h 315 mg/24 h 325 mg/24 h
min 55 ml/min 61 ml/min
1 0.031 0.030
Figure 1 Elechtropherogram showing the presence of the
c.2915C > T variant in heterozygosity. On the top the control, on
the bottom the mutated sequence.
Figure 2 Family tree of family under study. Black box indicates
the presence of PHPT, the arrow the presence of the mutation (see
text for clinical details).
Table 2 Laboratory results (comparison among father
and his affected son at genetic evaluation time)
Patient I:1 Patient’s affected
son II:3
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in order to investigate the protein conformation effect or
by quantitative assay to verify in addition the alteration
of protein function. In our functional assays on WT and
mutant CaSR proteins, we showed that, with respect the
WT, the 972 M variant is slightly underexpressed as far
as the 160 kDa glycosylated form (Figure 3). The signal-
ing activity of the 972 M mutant receptor, compared to
the WT, resulted strongly impaired even at higher Ca++
concentration (10 mM), showing a pattern similar to the
inactivating mutant control (Figure 4).Age at diagnosis 70 years old 41 years old
s-Ca total (n.v. 8.8-10.6) 12.96 mg/dl 10.3 mg/dl
S-Ca++ (n.v. 1.12-1.31) 1.62 mmol/l 1.30 mmol/l
s-PO4 (n.v. 2.7-4.5) 2.2 mg/dl 3.3 mg/dl
s-PTH (n.v. 5–40) 19.4 pg/ml 23.5 pg/ml
25(OH)vitamin D (n.v. 30–100) 40.7 ng/ml 12.3 ng/ml
U Ca (v.n. <4 mg/kg) 315 mg/24 h 195 mg/24 h
Cr Clearance (n.v. 70–120 ml/min) 55 ml/min 107 ml/min
Ca/Cr ratio 0.031 0.012Methods
Calcium, phosphorous and creatinine were measured by
automated laboratory methods. The urinary calcium and
creatinine measurements were carried out on spot and
on 24 h collection. PTH (Liaison 1–84 PTH, reference
values 5–40 pg/ml) and serum 25-OH-cholecalciferol
were determined by chemiluminescence immunoassay
(Diasorin-Liaison XL). Neck tomoscintigraphy was per-
formed by injection of 99Tc-sesta MIBI.Molecular analysis of CaSR gene
DNA was extracted from peripheral blood leukocytes using
standard protocol. Signed informed consent was obtained
from all the subjects and the protocol was approved by
local ethical committee of IRCCS “Casa Sollievo della
Sofferenza” Hospital (San Giovanni Rotondo). Genetic
screening of CaSR gene was performed by PCR amplification
and direct sequencing of all the 7 exons (12 amplicons) in-
cluding exon-intron boundaries as previously reported [18].
cDNA expression vectors and mutagenesis
The 972 M variant was introduced in a Myc tagged human
Wild Type (WT) CaSR cDNA expressing pCDNA3.1 vec-
tor: briefly, mutagenesis reaction was carried out with the
Figure 3 Western blot on protein extract. CaSR protein possesses
different levels of maturation in terms of post-translational modifications:
with respect to the WT, the 972 M mutant showed underexpressed the
fully mature glycosylated form of 160 kDa, while the other two bands
(the immature not-glycosylated 140 kDa form and the dimers band of
280 kDa) showed a normal pattern.
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Tggtcaccttctcactga- 3’ and Rev: 5’ -tcagtgagaaggtgacc
Atgccgctgccaaagatg- 3’, mutated base is in capital). One
microlitre of Dpn1 (New England Biolabs) digested the
parental DNA while 3 ul of reaction was used to transform
E.coli 5-alpha chemically competent cells (Lucigen). The
mutated clone was identified by colony PCR and sequen-
cing while midiprep performed with Plasmid Midi Kit
(QIAGEN).Figure 4 CaSR signaling activity measured as the ratio between the le
with the WT for both the Ca2+ concentrations, the 972 M variant induced a
the inactivating control (F351V). Values were normalized with respect to th
experiments. * = p <0.05 compared with the WT; b: a representative westerCell culture and transfection
Human Embrionic Kidney (HEK293, ECACC) cells were
cultured in DMEM/F12 (Sigma) supplemented with FBS
10% (Sigma) and penicillin/streptomycin 5% (SIGMA) at
37°C with CO2 5%.
Western blot on crude lysate protein extracts
200 thousands HEK293 cells were seeded in 12 wells
plates and transfected with Myc-tagged CaSR WT and
mutant vectors (T972M and F351V, this latter as inacti-
vating control) in triplicate. 48 hours after transfection,
total cell proteins were extracted in RIPA buffer [150
mMNaCl, 50 mM Tris–HCl, 1%, Nonidet P-40, 0.1% so-
dium dodecyl sulfate (SDS), 0.5% sodium deoxycholate,
pH 8.0] supplemented with one tablet/10 mL of Phos-
Stop and Complete EDTA, phosphatase and protease
inhibitors (both from Roche). 50 ug of proteins were
loaded onto a 8% SDS polyacrylamide gel, electrotrans-
ferred to PVDF membrane (Millipore, Billerica, MA),
blotted overnight at 4°C with rabbit anti Myc monoclo-
nal antibody (Cell Signaling Technology, 1:800 in block-
ing solution) and for 1 h at room temperature with the
horseradish peroxidase-conjugated goat anti-rabbit IgG
antibody (Santa Cruz Biotechnology) as secondary anti-
body. Membrane was stripped with Re-Blot Solution
(Millipore) and re-blotted with b-tubulin rabbit mono-
clonal antibody (Cell Signaling Technology, 1:1000 in
blocking solution) as loading control.vel of phosphorylated and total p42/44 proteins. a: compared
lower level of phosphorylation, similarly to the activity mediated by
e WT at 10 mM. Data are reported as mean ± SEM of three replicate
n blot was shown.
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750 thousand HEK293 cells were seeded in 6 wells plates
and transfected in 6 replicates with WT or mutant vectors
using Lipofectamine 2000 (Invitrogen). After 24 h cells
were starved with DMEM/F12 without Mg++ and with
minimal Ca++ concentration (0,5 mM final). 48 h after the
transfection, cells were stimulated in triplicates for each
vector with 4 or 10 mM CaCl2 for 5 min. Whole-cell ex-
tracts were made with RIPA buffer supplemented with
cocktail inhibitors as above described. 80 ug of proteins
were loaded onto a 12% SDS-PAGE and analyzed for ex-
pression of phosphorylated and total ERK1/2 proteins by
immunoblotting with rabbit Phospho p42/44 and rabbit
Total p42/44 antibodies, respectively (Cell Signaling Tech-
nology) according to the manufacturer’s protocol. Second-
ary antibody was as above described. The Image J-National
Institutes of Health image processing program (http://rsb.
info.nih.gov/ij/) was used for signal densitometry by de-
termining the ratios of the phosphorylated to nonpho-
sphorylated ERK1/2 signals at various extracellular calcium
concentrations and then normalized to the ratio of phos-
phorylated to unphosphorylated ERK1/2 at 10 mM [Ca++].
Statistical analysis
Results are expressed as mean and standard deviation
derived from triplicates experiments. A p-value < 0.05
was considered for statistical significance.
Discussion
Familial hyperparathyroidism is a wide spectrum of
disorders including multiple endocrine neoplasia types 1
(MEN 1) and 2A, hyperparathyroidism-jaw-tumor syn-
drome (HPT-JT), familial hypocalciuric-hypercalcemia
(FHH) and familial isolated hyperparathyroidism (FIHP)
[16,17]. We report the case of FHH (an adult men and his
son) affected by a novel mutation in CaSR gene. The
screening of the whole coding sequence of the CaSR gene
led to the identification of a novel variant of the exon 7,
namely c.2915C > T, p.T972M (Figure 1) in heterozygosity.
This variant was absent on the public CaSR database
(http://www.casrdb.mcgill.ca/; last access: may 2014) nor
on either the Mutation Discovery and 1000 Genomes
databases (http://www.mutationdiscovery.com/md/MD.
com/home_page.jsp; www.1000genomes.org/; last access:
may 2014), thus ruling out the possibility that it was a rare
polymorphism. The segregation analysis enlarged to the
available first degree relatives (Figure 2) allowed the iden-
tification of one carrier (II:3), the affected patient’s son,
a 41-year-old men, who is currently asymptomatic and
shows serum ionized calcium reaching upper value
(1.30 mmol/L) of normal range (1.12-1.31 mmol/L), nor-
mal calciuria and PTH. This point mutation, inherited in
heterozygosity and implicated in inactivating CaSR, leads
to a loss of function of the receptor, with evidence, in thefather, of hypercalcemia and unsuppressed PTH levels. In
classic form of this disorder, there is normal or hypocal-
ciuria (Ca/Cr ratio <0.01), as expected when there is a
point mutation confined in extracellular and transmem-
brane domains of CaSR.
In our subject, instead, there is evidence of hypercalciuria,
in line with Carling et al. study [19], that identified a family
with a heterozygous inactivating mutation of the cytoplas-
mic domain of the CaSR, not far from that of the patients
in our study, associated with hypercalcemia, hypercalciuria
and unsuppressed PTH. In that family, parathyroid surgery
was performed in seventeen kindreds and in some cases,
hyperplasia and nodule formations interpreted as single ad-
enoma were found. By contrast to these previous reports,
no image related to parathyroids hyperplasia or adenoma
was detected in both subjects. The presence of polycystic
kidney and jaw-cementoma in childhood can contribute to
ambiguity in distinguishing an atypical form of FHH from
HPT-JT. The absence of parathyroid adenoma, no visible
jaw-cementoma in the recent orthopantomography and
CaSR gene mutation, not associated to HPT, likely exclude
HPT-Jaw tumor syndrome. In our functional assays on WT
and mutant CaSR proteins, the western blot, performed on
protein crude lysates extracted from cells transfected with
WT and mutants CaSR vectors, showed that, with respect
to the WT, the 972 M variant is slightly underexpressed
as far as the 160 kDa glycosylated form. Instead either
the immature not-glycosilated 140 kDa and the higher
280 kDa band suggestive of the CaSR dimers, appeared
similar to the WT (Figure 3). The N-glycosylation at eight
sites (N-90, N-130, N-261, N-287, N-446, N-468, N-488,
and N-541) of the human CaSR have been proved to be
important for a proper cell surface expression [20,21]. The
process takes place in the ER and the fully glycosylation
ends in the Golgi. So far several CaSR mutations not spe-
cifically affecting the 8-N have been functional tested and
in many cases they showed a decrease of the expression of
the 160 kDA band [22,23]. In these cases an impairment
of the trafficking from the ER towards the Golgi is hypoth-
esized, rather than a defect in the N-glycosylation process
per se, even if in both the cases the final effect is a de-
crease of the cell surface expression [24]. With regard the
signaling activity of the mutant receptor, compared to the
WT, the 972 M mutant resulted strongly impaired even at
higher Ca++ concentration (10 mM), with a lower phos-
phorilation rate of ERK 1/2, showing a pattern similar to
the inactivating mutant control (Figure 4).
Conclusions
This is a case of a novel inactivating point mutation of
CaSR gene that determines an atypical clinical presenta-
tion of FHH with hypercalciuria. In the functional assays
we showed that the 972 M variant influenced the matur-
ation of the protein, in terms of the post-translational
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keeping with the specific localization of the 972 residue in
the C-terminal tail, which is assigned to the intracellular
signaling. It seems that this CaSR mutation influences the
intracellular signaling in parathyroid cells but not in kid-
ney, suggesting the existence in these two sites of distinct
intracellular pathways. The reported case may likely con-
tribute to enlarge the expanding clinical spectrum of CaSR
inactivating mutations.
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ing images. A copy of the written consent is available for
review by the Editor of this journal.
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